

RESEARCH ARTICLE

Risk of cerebrovascular stroke with primary percutaneous coronary intervention using thrombus aspiration device in stemi with high thrombus burden lesions: A single center experience

Ahmed Gaafar^{1*}, Khaled O. Abdulghani², Ahmed Basyouny³

¹Cardiology Department, Faculty of Medicine, Helwan University, Cairo, Egypt

²Neurology and Psychiatry Department, Faculty of Medicine, Helwan University, Cairo, Egypt

³Cardiology Department, Railways Medical Center, Cairo, Egypt

***Corresponding author:** Ahmed Gaafar, Cardiology Department, Faculty of Medicine, Helwan University, Cairo, Egypt. Email: Gaafar911@hotmail.com

Received: 29 January 2021; Accepted: 23 March 2021; Published: 30 April 2021

Abstract

Background: Early restoration of coronary flow in ST-segment elevation myocardial infarction (STEMI) reduces mortality, high thrombus burden has a higher incidence of no-reflow, stent thrombosis, LV dysfunction, and mortality, thrombus aspiration can reduce thrombus burden, but recent data suggest higher stroke incidence.

Objectives: We aimed in the study to determine the safety of the thrombus aspiration in high thrombus burden lesions in primary percutaneous coronary intervention (PPCI) for STEMI patients.

Methods: The study subjects included 100 patients who were divided into two groups: Group 1: Aspiration catheter was used in 46 patients with high thrombus burden, Group 2: 54 Patients with low thrombus burden, was managed with standard percutaneous coronary intervention (PCI) and thrombus aspiration as bailout only. Group A: patients who developed cerebrovascular stroke, Group B: who did not develop cerebrovascular stroke. Procedural complications and MACE data were obtained and follow-up for stroke incidence for 30 days.

Results: There were no differences between Group 1 and Group 2; or between Group A and Group B regards ST segment resolution, intra-procedural complications, re-infarction. No differences between Group 1 and Group 2 regards death and stroke. Group 1 had lower age, higher diabetes mellitus (DM) and smoking prevalence, lower ejection fraction (EF), and higher wall motion score index (WMSI) (48.76 vs 53.68, $P = 0.003$) (29.6% vs 54%, $p = 0.012$) (58% vs 33%, $p = 0.011$) (47% vs 51%, $p = 0.018$) (1.35 vs 1.21, $p = 0.0029$). Group A had lower EF, thrombolysis in myocardial infarction (TIMI) III flow, higher WMSI, higher no-reflow, and had higher mortality than Group B (34% vs 50%, $p = 0.0001$) (40% vs 81.3%, $p = 0.0165$) (1.65 vs 1.26, $p = 0.00015$) (60% vs 3%, $p = 0.00001$) (40% vs 2.1%, $p = 0.011$), respectively.

Conclusions: Thrombus aspiration did not cause a significant increase in stroke rate at 30 days. LV systolic dysfunction is an important risk factor for stroke during and after PPCI irrespective of the method of revascularization. The stroke had higher mortality in PPCI patients.

Keywords: aspiration catheter; CAD; direct stent; PCI; primary PCI; STEMI; stroke; thrombus burden

Introduction

The mechanism of acute ST-segment elevation myocardial infarction (STEMI) is the sudden thrombotic obstruction of the coronary flow.

Early restoration of blood flow plays a critical role in improving patient prognosis,¹ regardless of the method of reperfusion.^{2,3}

Direct stenting strategy is assumed as an effective method to limit microvascular dysfunction in

comparison to conventional stenting after using balloon dilatation with better myocardial perfusion and ECG ST resolution.^{4,5} Manual thrombus aspiration has been considered to decrease the risk of distal embolization and to improve myocardial reperfusion.⁶

Coronary thrombi while performing primary percutaneous coronary intervention (PPCI) is a bad prognostic factor with a higher incidence of adverse cardiac events.⁷ Acute myocardial infarction (AMI) patients with high thrombus burden (HTB) have a higher incidence of MACE, cardiac rupture, malignant arrhythmia, and LV systolic dysfunction due to inadequate myocardial perfusion.⁸

Furthermore, long-term data from the Study TAPAS⁹ and the meta-analyses^{10,11} suggested that the aspiration devices had good results regards the indices of myocardial perfusion which may lead to better clinical outcomes. Jolly et al. founded that in HTB, routine thrombus aspiration led to a significant reduction in 30-day all-cause mortality.¹² Of note, Grade 3 myocardial blush was achieved only in few patients in whom thrombolysis in myocardial infarction (TIMI) III flow was achieved with standard PPCI.¹³

However, the TOTAL Trial found that thrombus aspiration was associated with a higher risk of cerebrovascular (CV) stroke in STEMI patients who were routinely managed with thrombus aspiration plus PPCI versus PPCI alone.¹⁴ Possible explanations include catheter-related embolization, aggressive guide catheter manipulation which dislodges aortic atheroma, and longer procedure times.¹⁵ But we have no other reasonable explanations for the higher stroke rate even between 3 and 6 months and higher hemorrhagic stroke rate with thrombus aspiration.¹⁶

Aim of the study

We aimed in this study to determine the safety of the thrombus aspiration device in a special group of STEMI patients with high thrombus burden containing lesions during PPCI, during the hospital course, and outpatient period for 30 days with special concern to cerebrovascular stroke.

Methods

Study subjects enrolled in this study were 100 patients presented to the ER with acute STEMI

and they were referred to PPCI. The patients were divided into two groups according to thrombus burden.

Group 1 included 46 patients with high thrombus burden (TIMI thrombus Grade ≥ 4) before lesion stenting. An aspiration catheter was routinely used during PPCI.

Group 2 included 54 patients with lower thrombus burden (TIMI thrombus Grade < 4) who were managed with direct lesion stenting or balloon pre-dilatation with stenting, but aspiration catheter was used only as a bailout.

Thrombus grading was assessed after wiring the culprit lesion.

Then the patients were subdivided into two groups regards the development of cerebrovascular stroke.

Group A included the patients who developed cerebrovascular stroke.

Group B included the patients who did not develop cerebrovascular stroke.

For each enrolled patient, we collected the following data:

Clinical data: All the patients were subjected to a complete clinical assessment (full history and clinical examination), and the following data were reported:

Cardiac risk factors for coronary artery disease (CAD)

Diabetes Mellitus (DM) defined as HbA1c $\geq 6.5\%$, or random plasma glucose ≥ 200 mg/dl and symptoms of diabetes, or fasting plasma glucose ≥ 126 mg/dl, or patient on anti-diabetic treatment.¹⁷ **Hypertension (HTN)** was defined as systolic/diastolic blood pressure $\geq 140/90$ mmHg or patients having a history of HTN and current use of any antihypertensive medications.¹⁸ A family history of premature coronary artery disease (FH of PCAD) was defined as CAD in men less than 55 years or women less than 60 years.¹⁹ **Smoking** was recognized as a lifetime history of >100 cigarettes in their entire life and if patients had continued smoking in the last 6 months, it was considered a positive smoking history, while Ex-smokers were defined as those who had a history of smoking at least 100 cigarettes in their entire life and had completely stopped smoking for at least 6 months.²⁰ **Dyslipidemia** was defined

by total cholesterol ≥ 220 mg/dl, triglycerides ≥ 150 mg/dl, low-density lipoproteins (LDL cholesterol) ≥ 140 mg/dl, high-density lipoprotein (HDL cholesterol) ≤ 40 mg/dl, or current use of an anti-hyperlipidemia drug.¹⁹

ECG

Resting standard 12 leads electrocardiogram was done routinely at ER for each patient to detect ECG findings consistent with myocardial ischemia, arrhythmias, or chamber abnormalities.

Echocardiography

M-mode, two-dimensional echocardiography, and Doppler examination were performed for all patients in the left lateral decubitus position during normal respiration according to the recommendations of the American Society of Echocardiography to assess ventricular dimensions, systolic function by area length method at apical 4 and 2 chamber views, valvular morphology and flow, and to detect any wall motion abnormalities and assess wall motion score (WMS) and wall motion score index (WMSI), and to detect ischemic complications (ventricular septal rupture [VSR], myocardial rupture, LV aneurysm, LV thrombus).²¹

Laboratory data

Routine labs included complete blood count, coagulation profile, kidney functions, serum cardiac biomarkers that included cardiac troponin I (CTnI), the myocardial band of creatine kinase (CK-MB), and creatine kinase (CK).

Procedure-related data

Coronary artery anatomy was assessed by one single experienced cardiac catheterization physician, and the CAD extension was quantified and categorized. From the categorical viewpoint, coronary artery anatomy was defined as follows, obstructive CAD (any obstruction $> 70\%$, or $> 50\%$ if in the left main coronary artery or proximal left anterior descending coronary artery).

- a. **PCI procedure:** All Patients were pretreated with 300 mg of acetylsalicylic acid, 600 mg of clopidogrel, and intravenous heparin 10000 IU boluses administered during the procedure. All PPCI procedures were performed by experienced interventional cardiologists through a femoral approach.
- b. **Assessment of the thrombus score:** Assessment of the thrombus score was done in all patients. The decision to limit the procedure to direct stenting or thrombus aspiration before stenting was taken according to TIMI thrombus grade classification. If thrombus burden was ≥ 4 , the decision was aspiration device-use before stenting; if thrombus burden was < 4 , percutaneous coronary intervention (PCI) without thrombus aspiration was the procedure of choice. The use of Glycoprotein IIb/IIIa whether during the procedure or post-procedural was left to the operator's decision.

TIMI Thrombus score (Figure 1)

- i. TIMI thrombus **Grade 0:** No cine-angiographic characteristics of thrombus are present.
 - ii. TIMI thrombus **Grade 1:** Possible thrombus is present, with such angiography characteristics as reduced contrast density, haziness, irregular lesion contour, or a smooth convex "meniscus" at the site of total occlusion suggestive but not diagnostic of thrombus.
 - iii. TIMI thrombus **Grade 2** (small thrombus): There is a definite thrombus, with the greatest dimensions $\leq 1/2$ the vessel diameter.
 - iv. TIMI thrombus **Grade 3** (moderate thrombus): There is a definite thrombus but with the greatest linear dimension $> 1/2$ but < 2 vessel diameters.
 - v. TIMI thrombus **Grade 4** (large-sized thrombus): There is a definite thrombus, with the largest dimension ≥ 2 vessel diameters.
 - vi. TIMI thrombus **Grade 5:** There is total occlusion.²²
- c. **TIMI flow grade:** This method estimates the epicardial coronary flow by evaluating the flow rate of the contrast material during angiography. Four grades (0–3) have been defined:
- Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion.
 - Grade 1 (penetration without perfusion): The contrast material passes beyond the area of




Figure 1 TIMI thrombus grading. Grade 1: possible thrombus is present, with such angiography characteristics as reduced contrast density, haziness, irregular lesion contour, or a smooth convex “meniscus” at the site of total occlusion suggestive but not diagnostic of thrombus. Grade 2: there is definite thrombus, with greatest dimensions $\leq 1/2$ the vessel diameter, Grade 3: There is definite thrombus but with greatest linear dimension $> 1/2$ but < 2 vessel diameters. Grade 4: There is a definite thrombus, with the largest dimension ≥ 2 vessel diameters.




Figure 2 A case of acute inferior STMI with RCA TIMI thrombus Grade 5, (A) RCA with distal total occlusion with TIMI thrombus Grade 5, (B) thrombus grade did not change after wiring the RCA distally, (C) thrombus extracted by aspiration device demonstrated on gauze, (D) RCA TIMI III flow after thrombus aspiration with residual thrombi.

obstruction but “hangs up” and fails to opacify the entire coronary bed distal to the obstruction for the duration of the filming sequence.

Grade 2 (partial perfusion): The contrast material passes across the obstruction and opacifies the coronary bed distal to the obstruction. However, the rate of entry of

the contrast material or its clearance from the vessel distal to the obstruction (or both) is perceptibly slower than those in the opposite coronary artery or the coronary bed proximal to the obstruction.

Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction occurs

as promptly as antegrade flow into the bed proximal to the obstruction, and clearance of contrast material from the involved bed is as clearance from an uninvolved bed in the same vessel or the opposite artery.²³

Figure 2 shows a case of acute inferior STMI with right coronary artery (RCA) TIMI thrombus Grade 5, after the wire passed the thrombus and fixed distally, and the artery after thrombus aspiration shows TIMI III flow with mild residual thrombi.

Post-procedural

i. ECG:

A 12-lead ECG was done immediately after PCI, 60 min after PCI, 3 to 6 h later, and before discharge.

ii. Follow up data

Follow up was carried out during the hospital stay and outpatient period for 30 days for assessment of:

1. Major adverse cardiac events (MACE) as a composite of:
 - a. Death
 - b. Recurrence of myocardial infarction (whether with the same vessel or other vessel affection).
 - c. Occurrence of malignant arrhythmias.
 - d. Cerebrovascular nonfatal stroke.
2. Non-cardiac complications as hematoma to the puncture site, contrast-induced nephropathy, hospital-acquired infections.

Statistical analysis

Statistical analysis was carried out with SPSS 23.0 Package (IBM Inc., Chicago, Illinois, USA). Continuous variables were tested for normal distribution using Kolmogorov–Smirnov's test. Normally distributed data were presented as mean \pm SD and were compared by Student's t-test. Non-normally distributed data were presented as a median (first quartile, third quartile) and compared by Mann–Whitney U-test. Categorical variables were reported as a percentage and compared using χ^2 or Fisher's exact test. A two-sided P value of less than 0.05 was considered statistically significant.

Results

There was a statistically significant difference between Group 1 and Group 2 regards age, DM, and smoking, where age was lower in Group 1, while the prevalence of DM and smoking were higher in Group 1. There were no statistically significant differences regards to sex, HTN, dyslipidemia, and FH of PCAD. The male predominance was clear in both groups (Table 1).

There were no statistically significant differences between Group 1 and Group 2 regards, heart rate, Killip class, systolic blood pressure (SBP), diastolic blood pressure (DBP), CKMB, and troponin. But serum creatinine (s. creat) was statistically significantly lower in Group 1 (Table 1).

There were statistically significant differences between Group 1 and Group 2 regards ejection fraction (EF) and WMSI, where Group 1 had lower EF and higher WMSI. There was no statistically significant difference between Group 1 and Group 2 regards left ventricular end-diastolic diameter at diastole (LVEDd). There was no significant difference between Group 1 and Group 2 regards the incidence of LV systolic dysfunction (EF < 0.5) (Table 1).

There were no statistical differences between Group 1 and Group 2 regards the time of chest pain onset to first medical contact (FMC) and door to balloon time (Table 2).

There were no statistically significant differences between Group 1 and Group 2 regards the affected coronary artery or affected coronary artery segment (Table 2).

There was no statistically significant difference between Group 1 and Group 2 regards ST-segment resolution after coronary intervention (Table 2). There was no significant difference between Group 1 and Group 2 regards no-reflow and perforation (Table 2).

As regard stroke, there was no significant difference between Group 1 and Group 2. There was no significant difference between Group 1 and Group 2 regards death and re-infarction (Table 3).

In our study, all stroke cases occurred within the first week; four of them occurred within the first 48 h while the fifth case occurred on the sixth day.

There were no statistically significant differences regards to age, sex, DM, HTN, dyslipidemia, and smoking between Group A and Group B. But there was a statistically higher prevalence of a FH of PCAD in Group A (Table 1).

Table 1 Demographic data, clinical, laboratory, and echocardiographic data of Group 1 and Group 2, and between Group A and Group B.

	Group 1 (no:46)	Group 2 (no:54)	P G1 vs G2	Group A (no:5)	Group B (no:95)	P G: A vs G: B
Age (mean/years)	48.76	53.68	0.003	52.4	52.2	0.3
Sex						
M	43 (93%)	50 (92%)	0.8	5 (100%)	88 (92%)	0.4
F	3 (7%)	4 (8%)		0 (0%)	7 (8%)	
DM	25 (54%)	16 (29.6%)	0.012	2 (40%)	39 (41%)	0.6
HTN	21 (54%)	20 (37%)	0.38	3 (60%)	38 (40%)	0.58
Smoking	27 (58%)	18 (33%)	0.011	4 (80%)	41 (43%)	0.11
Dyslipidemia	14 (30%)	21 (39%)	0.4	2 (40%)	33 (35%)	0.4
F.H of PCAD	3 (7%)	5 (9%)	0.6	2 (40%)	6 (6.3%)	0.007
Heart rate (mean)	94.01	96.4	0.3	101	94	0.16
Killip Class no (%)						
I	28 (61%)	34 (63%)	0.7	2 (40%)	60 (63%)	0.37
II	11 (24%)	13 (25%)	1 (20%)	23 (24%)		
III	5 (11%)	3 (5%)	1 (20%)	7 (7%)		
IV	2 (4%)	4 (7%)	1 (20%)	5 (5.2%)		
SBP (mean)	126.7	120	0.08	121.5	125	0.09
DBP (mean)	78.1	75.6	0.25	77.3	76.6	0.3
High CKMB	36 (78%)	48 (85%)	0.14	5 (100%)	81 (85%)	1
High troponin	40 (86%)	45 (83%)	0.8	5 (100%)	80 (85%)	0.98
S.creat (mean) mg/dl	1.1 ± 0.3	1.26 ± 0.4.1	0.0003	1.01 ± 0.2	1.2 ± 0.183	0.06
LVEDd (CM)	5.76	5.5	0.25	6.0	5.7	0.1
EF	47%	51%	0.018	34%	50%	0.0001
WMSI	1.35	1.21	0.0029	1.65	1.26	0.00015
LV EF < 0.50	26 (48%)	28 (60%)	0.2			

DM; diabetes mellitus, HTN; hypertension, FH of PCAD; family history of premature CAD. SBP; systolic BP, DBP; diastolic BP. S.creat; serum creatinine. LVEDd; left ventricular end-diastolic diameter at diastole. EF; ejection fraction. WMSI; wall motion score index.

There were no statistically significant differences between Group A and Group B regards, heart rate, Killip class, SBP, DBP, CKMB, and troponin. But s. creat showed a trend to be lower in Group A (Table 1).

There were statistically significant differences between Group A and Group B regards EF and WMSI, where Group A had lower EF and higher WMSI. There was no statistically significant difference between Group A and Group B regards LVEDd (Table 1).

There were no statistical differences between Group A and Group B regards the time of chest pain onset to FMC, and door to balloon time (Table 2).

There were no statistically significant differences between Group A and Group B regards affected coronary artery or affected artery segment (Table 2).

There was no statistically significant difference between Group A and Group B regards ST-segment resolution after coronary intervention. Group A had a lower TIMI III flow than Group B (Table 2).

There was no significant difference between Group A and Group B regards dissection and perforation. But no-reflow was statistically higher in Group A than Group B (Table 2). There was no significant difference between Group A and Group B regards re-infarction. There was a significant difference between Group A and Group B regards death where it was higher in the stroke group (Table 3).

There was no significant difference between Group A and Group B regards atrial fibrillation (AF) arrhythmia and coronary artery thrombus grade (Table 4).

Discussion

This study was a single-center experience, retrospective study that was conducted on patients presenting with acute STEMI.

Table 2 Comparison of intervention findings between Group 1 and Group 2, and between-Group A and Group B.

		Group 1 (no:46)	Group 2 (no:54)	P-value G 1 vs G 2	Group A (no:5)	Group B (no:95)	P (G A vs G B)
Onset to FMC (h)		8.83	7.89	0.2	10.75	8.89	0.18
Door to balloon (min)		73.4	75.6	0.3	80.4	78.2	0.33
Affected artery	LM	1	0	0.8	0	1	0.08
	LAD	17	25		3	39	
	LCX	13	12		2	23	
	RCA	15	17		0	32	
Affected CA segment	Proximal	31	30	0.3	4	57	0.15
	Mid	7	14		1	20	
	Distal	8	10		0	18	
ST resolution post-PTCA		70%	67%	0.3	66.1%	69.2%	0.29
post-PTCA TIMI III flow. No (%)		30 (62%)	41 (75%)	0.24	2 (40%)	79 (83.1%)	0.0165
Complications	Perforation	0	1	1.0	0	1	1
	Dissection	2	0	0.2	0	2	1
	No reflow	0	3	0.2	3	3	0.00001

FMC; first medical contact. h; hour. min; minute. LM; left-main. LAD; left anterior descending coronary artery. LCX; left circumflex coronary artery. RCA; right coronary artery. ElectroCardioGram; ECG ST-segment. CA; coronary angiography.

Table 3 Hospital course complications of Group 1 and Group 2, and Group A and Group B.

	Group 1 (no:46)	Group 2 (no:54)	P (G 1 vs G 2)	Group A (no:5)	Group B (no:95)	P (G A vs G B)
Death	2	2	1	2	2	0.011
Stroke	4	1	0.17	0	2	1
Re-infarction	1	1	1			

Table 4 AF rhythm and CA thrombus grade in Group A and Group B.

		Group A (no:5)	Group B (no:95)	P
AF		1	3	0.19
Thrombus grade	≥4	4	42	0.17
	<4	1	53	

AF; atrial fibrillation, CA; coronary artery grade.

The aim was to evaluate the safety of manual thrombus aspiration in acute STEMI patients presented with high thrombus burden in comparison with conventional stenting during periods of hospital admission and up to 30 days with special concern to cerebrovascular stroke.

Despite the promising results of the early trials TASTE, TAPAS, and INFUSE-AMI regards coronary artery thrombus aspiration catheter in STEMI patients where it showed improved outcomes, however, the TOTAL trial failed to show mortality benefits.¹⁶ But in the scenario of patients with high thrombus burden containing lesions during

PCI, aspiration catheter still has a reasonable role to minimize residual intracoronary thrombus.²⁴

In our study, there was no significant difference between Group 1 and Group 2 regards cerebrovascular stroke incidence at 30 days follow up, and this is in agreement with the TASTE trial and Göran K et al.,²⁵ also Tung et al. found the incidence rates of stroke during the index hospitalization were 1.1 and 2.34 per 100 person-months in the thrombectomy and PCI alone groups, respectively (SHR: 0.59; 95% CI: 0.22 to 1.59; P = 0.3), or at 30 days (0.36 vs 0.84 per 100 person-months; SHR: 0.63; 95% CI: 0.27 to 1.45; P = 0.28) or even at 12 months follow-up (0.09 vs 0.15 per 100 person-months; SHR: 0.94, 95% CI: 0.53 to 1.69; P = 0.85), but Bekir S et al.²⁶ found similar data in their study during the hospital stay but stroke was higher in the group that was managed with thrombus aspiration (TA) at 30 months follow up. In our study, all stroke cases occurred within the first week, four of them occurred within the first 48 days while the fifth case occurred on the sixth day, and this was in agreement with Jeffrey T et al.,²⁷ study who found a median time to stroke is 6 days.

All our stroke cases were non-hemorrhagic strokes (100%) and this agreed with Jeffrey T et al.'s study where most cases were non-hemorrhagic stroke (88%). And as regard mortality, the stroke group had a higher rate of death than those without stroke (40% vs 2.1%, respectively) and it is expected especially in our study as they were STEMI patients with LV systolic dysfunction and complicated with acute cerebrovascular stroke. And it was found in the study done by Shmuel Fuchs et al.²⁸ that the mortality rate was higher during the hospital stay and up to 1 year in stroke patients, also in agreement with Jeffrey T et al., 2013²⁷ study where the stroke was associated with an increased risk of 30-day death (HR, 8.0; 95% CI, 4.2–12.8; $P < 0.001$). Stroke in our study had a higher incidence than most known reports, and actually, all of them occurred in patients with LV systolic dysfunction, even the single case of Group 2 had low EF which may suggest an embolic nature of the stroke more than procedure-related, which is in agreement with the study done by Jeffrey T et al.,²⁷ who found a higher incidence of congestive heart failure with stroke group vs those without stroke (7% vs 2%, respectively). And Shmuel Fuchs et al.²⁸ also found that LV was a source of stroke in four patients. We think the high incidence of LV systolic dysfunction (48% in Group 1 and 60% in Group 2) and the high incidence of stroke (4%) was a reflection of the long onset to balloon time which was about 10 h while it was about 2–3 h in the previous studies.^{1,16,38}

We did not find a difference in total death rate at 30 days between Group 1 and Group 2, although Group 1 had a lower systolic function and higher WMSI at presentation, and this may denote a potentiality for TA to offer a protective action in the patients with high thrombus burden. Bekir S et al.²⁶, found similar data in their study, also this was mentioned in the analysis done by Göran K et al.,²⁵ for TASTE trial, and in the TOTAL trial where there was no significant difference regards the mortality, also Tung et al. who found the incidence rates of all-cause mortality for the thrombectomy group and the PCI alone group at 30 days were 5.32 and 7.76 per 100 person-months, respectively (HR: 0.99; 95% CI 0.78 to 1.25, $P = 0.91$). Furthermore, the post-discharge mortality rate at 1 year was found to be lower in the subgroup of patients treated with aspiration thrombectomy by physicians with a high PPCI volume (HR: 0.47; 95% CI: 0.24 to 0.94; $P = 0.03$).²⁹ Carlos M et al.,³⁰ also found that patients with thrombus containing lesions tend to have

lower systolic function than those without thrombi (56.8 ± 11.9 versus 54.7 ± 11.9 ; $P = 0.052$).

The present study shows that men represented 93% of the total study population affected with STEMI while women represented only 7%, and this male predominance does not reflect the nature of the disease but it reflects the same pattern of employees' gender distribution in the company covered by the health center.

The mean age of the studied groups is 52.4 years, and this relatively young age may reflect the aggressive nature of CAD in these patients; this premature CAD may be due to the high incidence CAD risk factors (HTN 41%, DM 41%, smoking 45%, dyslipidemia 35%) and this in agreeing with (Yunyun et al., 2014),³¹ who stated that STMI in the young patients' group is explained by their lifestyles which is characterized by high work stress, fast pace, overwork, smoking, drinking alcohol, and overeating, that likely cause a disturbance in the internal environment, such as coronary atherosclerosis, that increase the incidence of AMI. Also, we found that the age of patients with higher thrombus burden was lower than those with lower thrombus burden; it may be due to the higher prevalence of DM and smoking in this group, and this is in agreement with Carlos M et al.,³⁰ who found patients with thrombus containing lesions had lower age than those without thrombi, but this was against the findings in the study done by Ibrahim Halil et al.,³² on 109 patients with STEMI to detect the determinants of angiographic thrombus, where he found that high thrombus burden group had higher age. The higher prevalence of DM and smoking in Group 1 may explain the high thrombus burden of this group, as Hyperglycemia promotes thrombosis, also erythrocyte aggregation is higher in diabetic than in non-diabetic patients, and hyperglycemia augments the expression of proinflammatory cytokines by stimulating inflammatory reaction.³³ Autopsy studies found the platelet adhesion and aggregation are higher in diabetic patients than non-diabetic ones.³⁴

Smoking is independently associated with fatal coronary thrombosis.³⁵ Smoking causes damage to the vascular endothelium through oxidative stress, vasoconstriction, and fibrinogen elevation that enhance thrombosis. Smoking also promotes platelet aggregation, blood viscosity, and activation of centrosomes,³⁶ which induces the expression of intercellular adhesion molecule-1, which initiates

immune-inflammatory responses, with subsequent coronary spasm and thrombosis.³⁷

There were no differences between high thrombus and low thrombus groups regards, gender, hypertension, and dyslipidemia, also, there were no differences between both groups in clinical findings as systolic BP, diastolic BP, heart rate, and Killip class and this was in agreement with Ibrahim Halil et al.³² and Ole Fröbert et al.³⁸ Also there were no differences between high thrombus and low thrombus groups regards cardiac biomarkers (CKMB and troponin), while, Ibrahim Halil et al. found a significant difference in these biomarkers, this may be because we had qualitative assessment (positive or negative at the time of presentation) of these markers, while Ibrahim Halil et al. study³² used a quantitative assessment (at presentation and the peak). Regarding s. creat, it was higher in patients with higher thrombus burden and this goes along with Dragu et al.³⁹ and Baris Sensoy et al.⁴⁰ who found that baseline renal impairment was associated with high thrombus burden.

In our study, there was no significant difference in the incidence of no-reflow between Group 1 and Group 2 and this comes in concomitant with Bekir S,²⁶ but Ibrahim Halil et al³² found a significant difference between both groups; we explained that in our study by the use of TA device in high thrombus burden group while Ibrahim Halil et al. did not use TA.

There was no significant difference between Group 1 and Group 2 regards atrial fibrillation (AF; as history or recently discovered at presentation or after MI) and this was in agreement with Bekir S et al.,²⁶ who also found no difference in AF history or even in AF incidence after MI.

The present study shows no significant difference in complications (perforation, coronary dissection) and re-infarction between Group 1 and Group 2 in the period of hospital admission, and this comes in concomitant with Bekir S²⁶ and Jamil et al. 2013,⁴¹ where there was no significant MACE recorded in the period of hospitalization and 4 weeks after discharge. And in agreement with the TOTAL trial,¹⁶ there was no difference in time of chest pain onset to FMC, door to balloon time, location of STEMI, affected vessel, or affected coronary artery segment between Group 1 and Group 2.

There was no difference between the group who developed CV stroke and those without stroke in age, history of DM, smoker, history of HTN, dyslipidemia, systolic BP, diastolic BP, heart rate, CKMB, s. creat, MI location, time from onset FMC and

door to balloon time, and this was similar to the findings in the study done by Jeffrey T et al. 2013,²⁷ except the history of DM which was higher in the stroke group. Also, there was no difference between the Group A and Group B regards Killip class and incidence of AF but, in the study done by Teffery T et al.,²⁷ they found a higher incidence of AF, higher Killip class, and higher age in the stroke group. Group A had a higher incidence of no-reflow and lower incidence of TIMI III flow, and this was explained by the presence of LV systolic dysfunction in all the patients in this group which was found also in Govindan N et al. study.⁴²

Conclusion

Left ventricular systolic dysfunction is an important risk factor for stroke during and after PPCI irrespective of the method of revascularization. Stroke leads to a higher mortality rate in patients with PPCI. The thrombus aspiration device did not cause a significant increase in stroke at 30 days and safe to be used in patients with high thrombus burden. Although the high thrombus burden group had lower LV systolic function and higher WMSI, they did not show higher MACE which is suggestive of a protective effect of thrombus aspiration in such high-risk category.

Limitations

To judge the safety of TA, we compared two groups with different TIMI thrombus grades. The follow-up period was 30 days and the stroke risk may persist up to 180 days in some previous studies. CKMB and troponin were qualitative only. All the procedures were done with clopidogrel only and only through the femoral approach. The studied sample was not equally sex-distributed.

Acknowledgments

Not applicable.

References

1. Marmagiolis K, Feldman DN, Charitakis K. Thrombus aspiration in STEMI. *Curr Treat Options Cardiovasc Med* [Internet].

- 2016 Jan;18(1):7. Available from: <https://doi.org/10.1007/s11936-015-0430-x>
2. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. *Circulation*. 2004 Mar;109(10):1223–5.
3. Brilakis ES, Reeder GS, Gersh BJ. Modern management of acute myocardial infarction. *Current Problems in Cardiology*. 2003.
4. Dudek D, Mielecki W, Burzotta F, Gasior M, Witkowski A, Horvath IG, et al. Thrombus aspiration followed by direct stenting: A novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish-Italian-Hungarian RANdomized ThrombEctomy Trial (PIHRAE Trial). *Am Heart J*. 2010;
5. Cuellas C, Fernández-Vázquez F, Martínez G, Trillo R, Vázquez N, Zueco J, et al. Direct stent implantation in acute myocardial infarction. The DISCO 3 Study. *Rev Española Cardiol (English Ed.)*. 2006;
6. Beran G, Lang I, Schreiber W, Denk S, Stefanelli T, Syeda B, et al. Intracoronary thrombectomy with the X-sizer catheter system improves epicardial flow and accelerates ST-segment resolution in patients with acute coronary syndrome: A prospective, randomized, controlled study. *Circulation*. 2002;
7. Svilaas T, Vlaar PJ, Van Der Horst IC, Diercks GFH, De Smet BJGL, Van Den Heuvel AFM, et al. Thrombus aspiration during primary percutaneous coronary intervention. *N Engl J Med*. 2008;
8. Ren H, Zheng Y, Hu X, Yang Y, Zhang Y, Sun Y, et al. High thrombus burden: A review of mechanisms and treatments. *Int J Clin Exp Med*. 2019; 12(11):13068–78.
9. Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, et al. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): A 1-year follow-up study. *Lancet*. 2008;
10. Burzotta F, De Vita M, Gu YL, Isshiki T, Lefvre T, Kaltoft A, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: An individual patient-data pooled analysis of 11 trials. *Eur Heart J*. 2009;
11. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: An updated meta-analysis of randomized trials. *J Am Coll Cardiol*. 2013;
12. Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: An individual patient meta-analysis: Thrombectomy trials collaboration. *Circulation*. 2017;
13. Srikanth S, Ambrose JA. Pathophysiology of coronary thrombus formation and adverse consequences of thrombus during PCI. *Curr Cardiol Rev*. 2012;
14. Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. *Lancet*. 2016;387(10014):127–35.
15. Jolly SS, Cairns JA, Yusuf S, Meeks B, Gao P, Hart RG, et al. Stroke in the TOTAL trial: A randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. *Eur Heart J*. 2015;
16. Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. *N Engl J Med*. 2015;372(15):1389–98.
17. Kilpatrick ES, Bloomgarden ZT, Zimmet PZ. International expert committee report on the role of the A1C assay in the diagnosis of diabetes: Response to the international expert committee. *Diabetes Care*. 2009.
18. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *Eur Heart J*. 2013;
19. Catapano AL, Graham I, De Backer G, Wiklund O, John Chapman M, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. *European Heart J*. 2016.
20. Leung Y, Kaplan GG, Rioux KP, Hubbard J, Kamhawi S, Stasiak L, et al. Assessment of variables associated with smoking cessation in crohn's disease. *Dig Dis Sci*. 2012;
21. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults (2015). *Eur Heart J Cardiovasc Imaging*. 2015;
22. Topaz O, Topaz A, Owen K. Thrombus grading for coronary interventions: The role of contemporary classifications. *Interventional Cardiology*. 2011.
23. Kern MJ, Moore JA, Aguirre F V., Bach RG, Caracciolo EA, Wolford T, et al. Determination of angiographic (TIMI grade) blood flow by intracoronary Doppler flow velocity during acute myocardial infarction. *Circulation*. 1996;
24. Gatto L, Di Landro A, Romagnoli E, Marco V, Russo C, Pawlowski T, et al. A comparison of intracoronary treatment strategies for thrombus burden removal during primary percutaneous coronary intervention: A COCTAIL II substudy. *Coron Artery Dis*. 2018;
25. Olivecrona GK, Lagerqvist B, Fröbert O, Gudnason T, Maeng M, Råmunddal T, et al. Impact of thrombus aspiration during ST-Elevation Myocardial Infarction: A six month composite endpoint and risk of stroke analyses of the TASTE trial. *BMC Cardiovasc Disord [Internet]*. 2016;16(1):1–10. Available from: <http://dx.doi.org/10.1186/s12872-016-0238-y>
26. Yildiz BS, Bilgin M, Zungur M, Alihanoglu YI, Kilic ID, Buber I, et al. Manual thrombus aspiration and the improved survival of patients with unstable angina pectoris treated with percutaneous coronary intervention (30 months follow-up). *Med (United States)*. 2016;95(8):1–11.
27. Gupta JT, Mehta RH, Armstrong PW, Horton J, Laskowitz D, James S, et al. Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction timing, characteristics, and clinical outcomes. *Circ Cardiovasc Interv*. 2013;6(2):176–83.
28. Fuchs S, Stabile E, Kinnaird TD, Mintz GS, Gruberg L, Canos DA, et al. Stroke complicating percutaneous coronary interventions: Incidence, predictors, and prognostic implications. *Circulation*. 2002;106(1):86–91.
29. Tung YC, See LC, Chang SH, Tu HT, Chan YH, Chang CJ. All-cause mortality and the risk of stroke with selective aspiration thrombectomy in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: A nationwide retrospective cohort study. *Medicine (Baltimore)*. 2020;
30. Campos CM, Costa F, Garcia-Garcia HM, Bourantas C, Suwannasom P, Valgimigli M, et al. Anatomic characteristics and clinical implications of angiographic coronary thrombus. *Circ Cardiovasc Interv*. 2015;8(4):1–9.
31. Yunyun W, Tong L, Yingwu L, Bojiang L, Yu W, Xiaomin H, et al. Analysis of risk factors of ST-segment elevation myocardial infarction in young patients. *BMC Cardiovasc Disord*. 2014;

32. Tanboga IH, Topcu S, Aksakal E, Kalkan K, Sevimli S, Acikel M. Determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction. *Clin Appl Thromb*. 2014;20(7):716–22.
33. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: Molecular mechanisms. *Cardiovascular Diabetology*. 2002.
34. Yunoki K, Naruko T, Inoue T, Sugioka K, Inaba M, Iwasa Y, et al. Relationship of thrombus characteristics to the incidence of angiographically visible distal embolization in patients with ST-segment elevation myocardial infarction treated with thrombus aspiration. *JACC Cardiovasc Interv*. 2013;
35. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: Association with different pathologies. *Circulation*. 2002;
36. Inoue T. Cigarette smoking as a risk factor of coronary artery disease and its effects on platelet function. *Tob Induc Dis*. 2004;
37. Scott D, Palmer R. The influence of tobacco smoking on adhesion molecule profiles. *Tob Induc Dis*. 2003;
38. Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. *N Engl J Med*. 2013;369(17):1587–97.
39. Dragu R, Behar S, Sandach A, Boyko V, Kapeliovich M, Rispler S, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? *Am J Cardiol*. 2006;
40. Şensoy B, Uzunget SB, Acikgoz SK, Sensoy N, Sen F, Acar B, et al. Renal dysfunction on admission predicts no-reflow phenomenon in patients undergoing manual thrombus aspiration during primary percutaneous coronary intervention. *Acta Cardiol Sin*. 2016;32(2):185–93.
41. Jamil G, Jamil M, Abbas A, Sainudheen S, Mokahal S, Qureshi A. “Lone aspiration thrombectomy” without stenting in young patients with ST elevation myocardial infarction. *Am J Cardiovasc Dis*. 2013;
42. Nair Rajesh G, Jayaprasad N, Madhavan S, Sudha Kumary V, Jayaprakash K, Raihanathul Misiriya KJ, et al. Predictors and prognosis of no-reflow during primary percutaneous coronary intervention. *Baylor Univ Med Cent Proc [Internet]*. 2019;32(1):30–3. Available from: <https://doi.org/10.1080/08998280.2018.1509577>